Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis

  title={Recycling and refurbishing old antitubercular drugs: the encouraging case of inhibitors of mycolic acid biosynthesis},
  author={Juan M Belardinelli and H. R. Morbidoni},
  journal={Expert Review of Anti-infective Therapy},
  pages={429 - 440}
  • Juan M Belardinelli, H. R. Morbidoni
  • Published 2013
  • Biology, Medicine
  • Expert Review of Anti-infective Therapy
  • One of the first approaches undertaken in the quest for antitubercular compounds was that of understanding the mechanism of action of old drugs and proposing chemical modifications or other strategies to improve their activity, generally lost to the mechanisms of resistance developed by Mycobacterium tuberculosis. A leading case was the work carried out on a set of compounds with proven activity on the essential pathway of the synthesis of mycolic acids. As a result, different solutions were… CONTINUE READING
    9 Citations

    Topics from this paper.

    The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone.
    • 14
    New prodrugs against tuberculosis.
    • 17
    Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones.
    • 39
    Interactions of isoniazid with membrane models: implications for drug mechanism of action.
    • 12


    Unique Mechanism of Action of the Thiourea Drug Isoxyl on Mycobacterium tuberculosis*
    • 126
    • PDF
    EthA, a Common Activator of Thiocarbamide-Containing Drugs Acting on Different Mycobacterial Targets
    • 117
    • PDF
    Mycolic acid synthesis: a target for ethionamide in mycobacteria?
    • 50
    • PDF
    Mechanism of thioamide drug action against tuberculosis and leprosy
    • 187
    • PDF
    Activation of the pro-drug ethionamide is regulated in mycobacteria.
    • 237
    • PDF
    Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors.
    • 62
    Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis.
    • 36